World Sleep Industry ENCYCLOPEDIA

Poria Extract

3.1.3

Starting material identity and entry boundary

Poria extract is a preparation made from the sclerotium of the poria fungus or, when explicitly disclosed, from cultured mycelium. Water, ethanol, or another suitable process is used before concentration and manufacture as a powder or liquid. Current fungal nomenclature commonly uses Wolfiporia cocos, while older literature and commerce frequently use Poria cocos. A specification should state the naming system, sclerotium or mycelium, geographic or fermentation origin, lot, and basis for identification rather than relying on “poria essence.”

Poria is fungal material and is not tu fu ling, the rhizome of the plant Smilax glabra. Whole sclerotium, poria peel, slices, powder, decoction, extract, purified polysaccharide, and an isolated triterpene are also different objects. This entry concerns an extract offered as a functional-food or supplement ingredient under WSIC 3.1.3. It is not a crude medicinal slice, a multi-herb medicine, or a drug authorized to treat insomnia. Catalog placement does not determine food authorization, medicinal status, or lawful health claims in any market.

Extraction, composition, and dose comparability

Poria sclerotium contains structurally diverse polysaccharides and multiple triterpenes. Hot water, alkaline media, different ethanol strengths, ultrasound, enzymes, precipitation, deproteinization, and purification alter yield, molecular size, solubility, triterpene profile, and residual impurities. Cultured mycelium can also differ substantially from cultivated sclerotium. A water-extracted polysaccharide, ethanol extract, fermented poria material, and total-triterpene fraction should therefore be identified as separate materials in research and procurement.

A ratio such as 10:1 or 20:1 usually describes one mass relationship between starting material and extract; it does not show how much of a relevant constituent was transferred. Dose comparison requires the actual extract mass per serving, starting material and part, solvent, extraction-ratio definition, yield, carrier proportion, standardization target, and analytical method. Passing a total-polysaccharide assay or one triterpene limit cannot simultaneously establish full identity, batch consistency, safety, and an effect on sleep.

Sleep evidence and limits on extrapolation

Sleep-related information includes traditional use, cellular and animal mechanisms, one small uncontrolled human study of a single extract, and a randomized trial of a combination. In the single-extract study, 21 people with poor sleep took 800 mg nightly of an extract prepared with 75% ethanol, and questionnaires and polysomnography were compared before and after use. There was no placebo or parallel control and the sample was small, so expectation, time, regression to the mean, and concurrent behavioral changes cannot be excluded. The research dose is not a universal product recommendation.

The randomized double-blind study combined poria, sour jujube seed, and GABA. Even if between-group sleep measures differ, that design cannot isolate the contribution of poria. Findings from an aqueous extract, ethanol extract, purified polysaccharide, mycelial preparation, or multi-ingredient formula should not be borrowed by another product. Credible finished-product evidence locks lot, process, fingerprint, serving, population, comparator, primary endpoint, blinding, adherence, and adverse events, and distinguishes questionnaires, actigraphy, and polysomnography.

Identity, quality, and production control

At the starting-material stage, macroscopic and microscopic examination, suitable DNA methods, and chemical identification may be combined to confirm the fungus and material used. Extraction removes morphology and may reduce recoverable DNA, increasing reliance on raw-material release, locked process parameters, mass balance, and a multi-attribute finished-product fingerprint. Specifications may cover water-soluble or acidic polysaccharides, representative triterpenes, solids, and carriers and should demonstrate lot consistency rather than release material by color, odor, one assay, or a supplier’s “pharmacopoeial grade” statement.

Risk-based controls should address moisture or water activity, microorganisms, mycotoxins, pesticide residues, toxic elements, sulfur dioxide, residual solvents, foreign matter, substitution, and undeclared drugs, together with blend uniformity, packaging compatibility, and stability through shelf life. A third-party report should identify the finished-product lot, sampling date, method, limit, and laboratory. A raw-material certificate does not replace control of the final product, and a change in supplier, origin, fermentation medium, or extraction parameters calls for a documented comparability assessment.

Safety, populations, and response to adverse events

Human safety information is limited for single-ingredient poria extracts across long duration, high exposure, and different processes. Possible problems must be assessed for the actual product and may include gastrointestinal discomfort, skin or respiratory allergic manifestations, and reactions to excipients. An event with a combination cannot automatically be attributed to poria, while absence of reported events does not establish that adverse effects are impossible. Persistent vomiting, marked rash, breathing difficulty, altered consciousness, or another serious symptom warrants discontinuation and timely assessment, with packaging, lot, and co-used products retained as information.

Pregnancy, breastfeeding, childhood, impaired liver or kidney function, the perioperative period, and long-term medicine use call for particular caution because product-specific information is sparse. A history of poria as food does not automatically cover every solvent, concentration, and dose. Drug interactions should likewise not be managed through a universal spacing rule inferred from a proposed mechanism; a clinician or pharmacist should review the exact preparation, medicines, and health context.

Labeling, compliance, and procurement review

Labels and technical documents should identify the fungal name and common synonym, sclerotium or mycelium, extraction solvent and ratio, actual extract mass, calculation of starting-material equivalent, standardization target, carrier and other excipients, suggested servings, lot, dates, storage, and responsible operator. “High-ratio,” “cell-wall broken,” “high polysaccharide,” “wild,” “authentic origin,” and “pharmacopoeial grade” require defined criteria and batch evidence and cannot replace a complete specification.

China’s food–medicine substance catalog, pharmacopoeial identity, health-food ingredients, ordinary foods, and medicines are distinct regulatory questions. Cross-border products require a fresh review under the destination market’s current ingredient, extraction, dosage-form, and claim rules. Procurement covers supplier qualification, identity methods, process changes, batch fingerprints, contaminants, stability, retention samples, complaints, and recall. A laboratory result speaks only to the tested sample and analytes; a patent, paper, or testing logo is not official certification of sleep efficacy.

Use management, industry evaluation, and related entries

Before evaluating a product, record its full name, lot, material form, process, amount per serving, combination ingredients, and intended use, and avoid starting several sleep products at once. If limited observation follows professional review, keep schedule, light, caffeine, alcohol, and other sleep measures reasonably stable and record sleep, next-day function, and discomfort. Lack of reproducible benefit is not a reason to increase the dose, switch to a higher-ratio extract, or stack products marketed as sedating. Persistent insomnia, suspected breathing pauses, or abnormal daytime sleepiness needs separate professional assessment.

Industry evaluation should consider traceability of sclerotium cultivation or mycelial fermentation, use of pine or other resources, extraction yield, solvent recovery, disclosure of carriers, lot consistency, and waste management. Related entries include fleeceflower caulis extract, arborvitae seed extract, sour jujube seed extract, poria-and-lily pastes, and pre-sleep soothing teas. Related reading supports comparison of material, process, evidence, and risk; it is not a recommendation for combined use or treatment of disease.